Drug intelligence / Profile preview

STI-6991

Development stage: Preclinical
Lead developer: Sorrento Therapeutics
Modality: Cell Therapies, Vaccines & Immunotherapeutics

Overview

STI-6991 is an investigational **cellular vaccine** and biologic developed by Sorrento Therapeutics for the prevention of COVID-19. It is described as an I-Cell decoy cellular vaccine composed of replication-deficient human erythroleukemia K562 immune-training cells engineered to express membrane-bound S1 protein from SARS-CoV-2 on the cell surface. By displaying viral antigen on a cellular membrane, the product is intended to function as a decoy immunogen that induces both **B-cell mediated antibody responses** and **T-cell mediated cellular immunity** against SARS-CoV-2. Publicly available context indicates the program was being discussed with the FDA for IND-enabling studies in 2020.

Other names: I-Cell COVID-19 decoy cellular vaccine

Beyond the preview

Go deeper on STI-6991.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STI-6991.

Explore the full profile